TRELSTAR - I'm Using Trelstar

I'm Using TRELSTAR
If you've come to this section of TRELSTAR.com you have most likely spent time with your doctor discussing the various treatment options available for your prostate cancer. TRELSTAR may be one of those options selected.

You should become as familiar with TRELSTAR as you can so you know what to expect during your treatment.

TRELSTAR is a type of prescription drug known as an LHRH agonist. These types of drugs are used to treat advanced prostate cancer by depriving cancer cells of the male hormones, such as testosterone, needed for growth. Triptorelin, the active ingredient in TRELSTAR, has been used in over 80 countries world wide for over 20 years.

Some side effects may be experienced with LHRH agonist type of medications. It may help you to understand what side effects you may experience, and work with your doctor to learn how you may better manage these.

Know that you are not alone. As of 2005 it is estimated that over 2 million American men are living with prostate cancer. There are a number of support groups and resources available to help you during this time.

Remember that your healthcare provider is the best resource available to you. We hope your visit at TRELSTAR.com provides you with information and tools that may help you work with your doctor for your prostate cancer care.

Indications and Usage
TRELSTAR^® Depot and TRELSTAR^® LA are indicated in the palliative treatment of advanced prostate cancer. TRELSTAR Depot or TRELSTAR LA offer an alternative treatment for prostate cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.

Safety Information

The most commonly reported adverse events associated with the use of TRELSTAR^® Depot/TRELSTAR^® LA included hot flushes (58.6%/73.0%), skeletal pain (12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%), and edema in legs (0.0%/6.3%) . TRELSTAR is contraindicated in women who are or may become pregnant as well as patients who are hypersensitive to triptorelin, other LHRH agonists, or LHRH . Infrequent postmarketing reports of anaphylactic shock and angioedema have been received since 1986 (global experience) . As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels. Patients may experience the onset or exacerbation of symptoms during this period, including bone pain, neuropathy, hematuria, spinal cord compression, or urethral or bladder outlet obstruction. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed.